Table 9. Sensitivity (%) and 95% confidence intervals (95% CI) of Kalazar Detect performed at the point of care (POC) and IT-Leish and other tests performed at IMT, in serum samples collected from patients with VL/aids, according to the collection site.
Locality (n) | Sensitivity % (n) | ||||
---|---|---|---|---|---|
CI 95% | |||||
KD-POC | KD-IMT | IT-Leish | IFA | ELISA | |
Campo Grande (11) | 81.8 (9) | 63.6 (7) | 72.7 (8) | 72.7 (8) | 81.8 (9) |
79.2–97.3 | 35.4–84.8 | 43.4–90.3 | 43.4–90.3 | 79.2–97.3 | |
Bauru (5) | 80.0 (4) | 80.0 (4) | 80.0 (4) | 80.0 (4) | 80.0 (4) |
37.6–96.4 | 37.6–96.4 | 37.6–96.4 | 37.6–96.4 | 37.6–96.4 | |
Natal (4) | 25.0 (1) | 25.0 (1) | 25.0 (1) | 75.0 (3) | 75.0 (3) |
4.56–70.0 | 4.6–69.9 | 4.6–69.9 | 30.1–95.4 | 30.1–95.4 | |
Total (20) | 70.0 (14) | 60.0 (12) | 65.0 (13) | 75.0 (15) | 80.0 (16) |
48.1–85.5 | 38.7–78.1 | 43.3–81.9 | 53.1–88.8 | 58.4–91.9 |
n–number of samples.
KD-POC–Kalazar Detect performed at the point of care.
KD-IMT–Kalazar Detect processed at IMT.
IT-Leish–rK39 –RDT.
IFA–L. major-like based Indirect immunofluorescence assay.
ELISA–L. major-like based Enzyme-linked immunosorbent assay.
No difference across localities (chi-square test, p>0.05) or tests (McNemar’s test, p>0.05).